Pegaspargase

Generic Name
Pegaspargase
Brand Names
Oncaspar
Drug Type
Biotech
Chemical Formula
-
CAS Number
130167-69-0
Unique Ingredient Identifier
7D96IR0PPM
Background

Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synt...

Indication

Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL)
Associated Therapies
-

ALL Adult Consortium Trial: Adult ALL Trial

First Posted Date
2007-05-21
Last Posted Date
2024-04-17
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
112
Registration Number
NCT00476190
Locations
🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Children's Hospital of Boston, Boston, Massachusetts, United States

and more 12 locations

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2007-02-27
Last Posted Date
2020-02-19
Lead Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Target Recruit Count
31
Registration Number
NCT00440726
Locations
🇨🇦

Sick Kids, Toronto, Ontario, Canada

🇺🇸

Childrens Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

and more 21 locations

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

First Posted Date
2007-02-23
Last Posted Date
2021-03-17
Lead Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Target Recruit Count
9
Registration Number
NCT00439296
Locations
🇺🇸

Stanford University Medical Center, Palo Alto, California, United States

🇺🇸

Childrens Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States

and more 2 locations

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

First Posted Date
2006-12-05
Last Posted Date
2024-10-21
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
1895
Registration Number
NCT00408005
Locations
🇺🇸

Scott and White Memorial Hospital, Temple, Texas, United States

🇺🇸

Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 212 locations

Treatment of Acute Lymphoblastic Leukemia in Children

First Posted Date
2006-11-17
Last Posted Date
2024-11-27
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
800
Registration Number
NCT00400946
Locations
🇨🇦

McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada

🇺🇸

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States

🇨🇦

Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada

and more 5 locations

Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Not Applicable
Conditions
First Posted Date
2006-06-23
Last Posted Date
2013-08-26
Lead Sponsor
Universitätsklinikum Hamburg-Eppendorf
Target Recruit Count
550
Registration Number
NCT00343369
Locations
🇩🇪

Dr. von Haunersches Kinderspital der Universitaet Muenchen, Munich, Germany

🇩🇪

Kreskrankenhaus Kinderabteilung, Heide, Germany

🇩🇪

Universitaets - Kinderklinik, Leipzig, Germany

and more 13 locations

Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses

First Posted Date
2005-09-19
Last Posted Date
2009-09-30
Lead Sponsor
Nordic Society for Pediatric Hematology and Oncology
Target Recruit Count
85
Registration Number
NCT00192673
Locations
🇩🇰

Department of Pediatrics, Skejby Hospital, Aarhus, Aarhus N, Denmark

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

First Posted Date
2005-02-08
Last Posted Date
2021-06-14
Lead Sponsor
Children's Oncology Group
Target Recruit Count
5377
Registration Number
NCT00103285
Locations
🇺🇸

Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States

🇺🇸

Driscoll Children's Hospital, Corpus Christi, Texas, United States

🇨🇦

Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke, Quebec, Canada

and more 233 locations

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2004-12-09
Last Posted Date
2017-12-12
Lead Sponsor
Children's Oncology Group
Target Recruit Count
134
Registration Number
NCT00098839
Locations
🇺🇸

Indiana University Medical Center, Indianapolis, Indiana, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Seattle Children's Hospital, Seattle, Washington, United States

and more 43 locations
© Copyright 2024. All Rights Reserved by MedPath